Wim Van Criekinge

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

M. Gilbert, R. Stupp, M. Weller, 2018, Clinical Cancer Research.